Literature DB >> 8863737

Characterization of new human c-myc mRNA species produced by alternative splicing.

M Bodescot1, O Brison.   

Abstract

Characterization of two human c-myc cDNAs corresponding to the mRNAs 2.5 and 3.1 kb in length transcribed from P0 previously demonstrated the existence of alternative acceptor sites at the end of intron 1 and intron 2, respectively [Bentley, D.L. and Groudine, M. (1986) Mol. Cell. Biol. 6, 3481-3489]. We investigated the use of these alternative acceptor sites in each c-myc mRNA species. We characterized cDNAs corresponding to c-myc mRNAs transcribed in the SW613-S human carcinoma cell line. The use of the alternative acceptor site at the end of intron 1 was demonstrated in two out of 10 cDNAs corresponding to the 3.1-kb mRNA transcribed from P0 and in three out of 10 cDNAs corresponding to the mRNAs transcribed from P1 or P2. The use of this acceptor site is therefore not restricted to the 2.5-kb mRNA transcribed from P0. The mRNAs resulting from the use of this acceptor site is therefore not restricted to the 2.5-kb mRNA transcribed from P0. The mRNAs resulting from the use of this acceptor site would encode for a variant form of the p67 polypeptide lacking one amino-acid residue. Conversely, the use of the alternative acceptor site at the end of intron 2 was not found in any of the cDNAs corresponding to the mRNAs transcribed from P0 (0/10), from P1 or P2 (0/10) and from P3 (0/10). In the course of this study, we isolated a cDNA corresponding to another new c-myc mRNA species. This mRNA is produced by alternative splicing within intron 1 and encodes only for p64.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863737     DOI: 10.1016/0378-1119(96)00464-7

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

Authors:  Y Shi; Y Yang; B Hoang; C Bardeleben; B Holmes; J Gera; A Lichtenstein
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

2.  Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters.

Authors:  Miltiadis Kininis; Benjamin S Chen; Adam G Diehl; Gary D Isaacs; Tong Zhang; Adam C Siepel; Andrew G Clark; W Lee Kraus
Journal:  Mol Cell Biol       Date:  2007-05-21       Impact factor: 4.272

3.  High frequency trans-splicing in a cell line producing spliced and polyadenylated RNA polymerase I transcripts from an rDNA-myc chimeric gene.

Authors:  Célia Chen; Nicole Fossar; Dominique Weil; Marine Guillaud-Bataille; Gisèle Danglot; Brigitte Raynal; François Dautry; Alain Bernheim; Olivier Brison
Journal:  Nucleic Acids Res       Date:  2005-04-22       Impact factor: 16.971

4.  Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility.

Authors:  Xavier Solé; Pilar Hernández; Miguel López de Heredia; Lluís Armengol; Benjamín Rodríguez-Santiago; Laia Gómez; Christopher A Maxwell; Fernando Aguiló; Enric Condom; Jesús Abril; Luis Pérez-Jurado; Xavier Estivill; Virginia Nunes; Gabriel Capellá; Stephen B Gruber; Víctor Moreno; Miguel Angel Pujana
Journal:  BMC Genomics       Date:  2008-01-11       Impact factor: 3.969

5.  Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies.

Authors:  Hugo Caldas; Laura E Honsey; Rachel A Altura
Journal:  Mol Cancer       Date:  2005-03-02       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.